Publication:
Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool

Loading...
Thumbnail Image

Author

Figueroa-Campos, Andrés Ignacio
Sánchez-Dengra, Bárbara
Merino, Virginia
Dahan, Arik
Gonzalez-Alvarez, Isabel
García Arieta, Alfredo
Gonzalez-Alvarez, Marta
Bermejo, Marival

Journal Title

Journal ISSN

Volume Title

Date

Citation

Pharmaceutics 2020, 12(7), 633;

Conference

Publisher

MDPI

Abstract

The main objective of this investigation was to develop an in vitro–in vivo correlation (IVIVC) for immediate release candesartan cilexetil formulations by designing an in vitro dissolution test to be used as development tool. The IVIVC could be used to reduce failures in future bioequivalence studies. Data from two bioequivalence studies were scaled and combined to obtain the dataset for the IVIVC. Two-step and one-step approaches were used to develop the IVIVC. Experimental solubility and permeability data confirmed candesartan cilexetil. Biopharmaceutic Classification System (BCS) class II candesartan average plasma profiles were deconvoluted by the Loo-Riegelman method to obtain the oral fractions absorbed. Fractions dissolved were obtained in several conditions in USP II and IV apparatus and the results were compared calculating the f2 similarity factor. Levy plot was constructed to estimate the time scaling factor and to make both processes, dissolution and absorption, superimposable. The in vitro dissolution experiment that reflected more accurately the in vivo behavior of the products of candesartan cilexetil employed the USP IV apparatus and a three-step pH buffer change, from 1.2 to 4.5 and 6.8, with 0.2% of Tween 20. This new model was able to predict the in vivo differences in dissolution and it could be used as a risk-analysis tool for formulation selection in future bioequivalence trials.

Journal Title

DOI

Center

Department

ISBN

Subjects

Advisor

Alternative title

Funder